Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $660 | $528 | $500 | $594 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $22 | $22 | $46 | $49 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $32 | $37 | $38 | $71 |
| Total Curr. Assets | $714 | $587 | $584 | $714 |
| Property Plant & Equip (Net) | $181 | $194 | $205 | $233 |
| Goodwill | $162 | $164 | $158 | $149 |
| Intangibles | $322 | $341 | $336 | $336 |
| Long-Term Investments | $0 | $6 | $0 | $0 |
| Tax Assets | $1 | $1 | $2 | $2 |
| Other NC Assets | $19 | $9 | $20 | $14 |
| Total NC Assets | $685 | $715 | $721 | $734 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,400 | $1,302 | $1,305 | $1,449 |
| Liabilities | – | – | – | – |
| Payables | $14 | $19 | $25 | $22 |
| Short-Term Debt | $20 | $20 | $20 | $22 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $47 | $40 | $40 | $62 |
| Other Curr. Liab. | $73 | $85 | $57 | $82 |
| Total Curr. Liab. | $155 | $164 | $142 | $187 |
| LT Debt | $62 | $68 | $72 | $86 |
| Deferred Rev, NC | $0 | $126 | $0 | $119 |
| Deferred Tax Liab, NC | $23 | $24 | $22 | $17 |
| Other NC Liab. | $112 | $2 | $134 | $5 |
| Total NC Liab. | $197 | $219 | $229 | $226 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $65 | $0 | $81 |
| Total Liabilities | $353 | $383 | $371 | $414 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,968 | -$1,806 | -$1,634 | -$1,431 |
| AOCI | $34 | $44 | $14 | -$8 |
| Other Equity | $2,981 | $2,681 | $2,553 | $2,474 |
| Total Equity | $1,047 | $919 | $934 | $1,035 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,400 | $1,302 | $1,305 | $1,449 |
| Net Debt | -$577 | -$440 | -$408 | -$486 |